

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 29435

Title: Role of lipid-lowering agents in the management of diabetic retinopathy

Reviewer's code: 00506239

Reviewer's country: Italy

Science editor: Xue-Mei Gong

Date sent for review: 2016-08-16 11:42

Date reviewed: 2016-08-16 17:13

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The authors evaluated the data from literature regarding the role of lipid-lowering agents in the management of diabetic retinopathy. The text is clear and well-written; however, I have some comments for the authors: - The pathogenesis of diabetic retinopathy: this part is weak: I suggest to go more in depth describing all different hypotheses. - A structured table showing the main studies can be useful for the readers. - The conclusion of the last part of the text is the same of the abstract: I suggest to modify it

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 29435

Title: Role of lipid-lowering agents in the management of diabetic retinopathy

Reviewer's code: 00506250

Reviewer's country: Japan

Science editor: Xue-Mei Gong

Date sent for review: 2016-08-16 11:42

Date reviewed: 2016-08-20 18:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This editorial on the management of diabetic retinopathy by lipid-lowering agents is clearly written and informative. I have no additional comments.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 29435

Title: Role of lipid-lowering agents in the management of diabetic retinopathy

Reviewer's code: 00506276

Reviewer's country: Poland

Science editor: Xue-Mei Gong

Date sent for review: 2016-08-16 11:42

Date reviewed: 2016-08-30 20:33

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The purpose of this review is to summarize the current knowledge about the effect of lipid-lowering drugs on the development of diabetic retinopathy. The topic is very important. This brief review is overall quite well-written. Both the mechanisms through which statins and fibrates may modulate the development of retinopathy and the results of clinical trials are presented. The only concern is that some introduction about molecular mechanisms of statin and fibrate activity should be included; it would be helpful for the reader. In addition, it would be suitable to include some figure presenting the most important molecular pathogenetic mechanisms involved in diabetic retinopathy development.